Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chemoradiation Plus tisLelizumAb for Conversion Therapy of Locally Nonresectable ESCC

NCT05394415 is registered in ClinicalTrials.gov with Jiangsu Cancer Institute & Hospital as lead sponsor.

NCT NCT05394415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05394415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chemoradiation Plus tisLelizumAb for Conversion Therapy of Locally Nonresectable ESCC
Lead sponsor
Jiangsu Cancer Institute & Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 1, 2022
Completion date
April 30, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemoradiation, esophageal squamous cell carcinoma, tislelizumab